200,000+ products from a single source!
sales@angenechem.com
100648-13-3 | 1H-Benzimidazole, 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfinyl)-
CAS No: 100648-13-3 Catalog No: AG0002KW MDL No:MFCD09038493
Product Description
Catalog Number:
AG0002KW
Chemical Name:
1H-Benzimidazole, 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfinyl)-
CAS Number:
100648-13-3
Molecular Formula:
C14H9Cl3N2O2S
Molecular Weight:
375.6575
MDL Number:
MFCD09038493
IUPAC Name:
6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfinyl-1H-benzimidazole
InChI:
InChI=1S/C14H9Cl3N2O2S/c1-22(20)14-18-9-5-8(16)12(6-10(9)19-14)21-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)
InChI Key:
GABQPFWIQFRJSE-UHFFFAOYSA-N
SMILES:
Clc1cc2[nH]c(nc2cc1Oc1cccc(c1Cl)Cl)S(=O)C
Properties
Complexity:
431
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
373.945g/mol
Formal Charge:
0
Heavy Atom Count:
22
Hydrogen Bond Acceptor Count:
4
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
375.648g/mol
Monoisotopic Mass:
373.945g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
74.2A^2
Undefined Atom Stereocenter Count:
1
Undefined Bond Stereocenter Count:
0
XLogP3:
4.4
Literature
| Title | Journal |
|---|---|
| A novel MDCKII in vitro model for assessing ABCG2-drug interactions and regulation of ABCG2 transport activity in the caprine mammary gland by environmental pollutants and pesticides. | Toxicology in vitro : an international journal published in association with BIBRA 20140401 |
| Development of an egg hatch assay for the diagnosis of triclabendazole resistance in Fasciola hepatica: proof of concept. | Veterinary parasitology 20120210 |
| Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica. | Parasitology research 20111001 |
| Residual concentrations of the flukicidal compound triclabendazole in dairy cows' milk and cheese. | Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment 20110401 |
| Interaction of anthelmintic drugs with P-glycoprotein in recombinant LLC-PK1-mdr1a cells. | Chemico-biological interactions 20100805 |
| Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica. | Parasitology research 20100501 |
| Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes. | BMC veterinary research 20100101 |
| Detoxifying and anti-oxidant enzymes of Fasciola gigantica worms under triclabendazole sulphoxide (TCBZ-SX): an in vitro study. | Journal of the Egyptian Society of Parasitology 20090401 |
| Relative activity of triclabendazole metabolites against the liver fluke, Fasciola hepatica. | Veterinary parasitology 20090205 |
| Pharmacokinetic disposition of triclabendazole in cattle and sheep; discrimination of the order and the rate of the absorption process of its active metabolite triclabendazole sulfoxide. | Veterinary research communications 20080101 |
| Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect. | The Journal of parasitology 20061201 |
| Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in the mouse model. | The American journal of tropical medicine and hygiene 20060801 |
| Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep. | Journal of veterinary pharmacology and therapeutics 20060601 |
| Drug transport mechanisms in helminth parasites: passive diffusion of benzimidazole anthelmintics. | Experimental parasitology 20060501 |
| Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. | Parasitology research 20041201 |
| The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. | Parasitology research 20040201 |
| Fasciola gigantica: tegumental surface alterations following treatment in vitro with the sulphoxide metabolite of triclabendazole. | Parasitology research 20020401 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.